

Date: 8th November, 2023

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APL LTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Unaudited Financial Results for the quarter and half year ended 30th September, 2023, published in 'Economic Times & Indian Express (English Edition)' and Financial Express (Gujarati Edition) on 8th November, 2023.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Marijana Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodra - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.09.2023	30.09.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,594.93	1,475.01	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	134.64	151.31	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	134.64	151.31	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	136.56	133.35	341.99
Total Comprehensive Income for the period	137.12	139.57	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	6.95	6.78	17.40
Research and Development Expenses	121.13	167.65	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.09.2023	30.09.2022	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,478.84	1,354.42	5,149.00
Profit Before Tax	133.84	167.00	345.93
Profit After Tax	133.84	146.44	346.73
Research and Development Expenses	120.70	162.06	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Panetarav

Chirayu Amin

Date: 7th November, 2023

Chairman and CEO



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC006123
 Regd. Office: Alembic Road, Vadodra - 390 002
 Tel: 022-6627200
 Email: ap.investors@alembic.co.in
 Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.09.2023	31.08.2023	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,564.62	1,475.01	5,852.52
Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	134.84	151.31	354.58
Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	134.84	151.31	354.58
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/or Extraordinary Items)	136.66	133.35	341.98
Total Comprehensive Income for the period	137.12	138.57	356.36
Equity Share Capital	39.31	38.31	38.31
Earnings Per Share (Face Value of ₹ 5/- each) Basic & Diluted	6.95	6.78	17.48
Research and Development Expenses	121.13	167.65	721.94

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.09.2023	31.08.2023	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,476.34	1,354.42	5,149.89
Profit Before Tax	131.84	167.35	345.55
Profit After Tax	131.84	145.44	345.73
Research and Development Expenses	126.76	162.85	689.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchanges website at www.secdisc.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

30

Place: Vadodra

Chitayu, Arjun

Date: 7th November, 2023

Chairman and CEO



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L14230GJ2019PLC091723
 Regd. Office: Alembic Road, Vadodra - 390 003
 Tel: 0245-4637300
 Email: apt.investors@alembic.co.in
 Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.09.2023	30.09.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,594.63	1,475.01	5,852.62
Net Profit for the period before Tax, Exceptional and/or Extraordinary Items	134.84	151.31	354.58
Net Profit for the period before tax (after Exceptional and/or Extraordinary Items)	134.84	151.31	354.58
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/or Extraordinary Items)	136.56	133.35	341.86
Total Comprehensive Income for the period	137.12	136.57	356.36
Equity Share Capital	36.31	36.31	36.31
Earning Per Share (Face Value of ₹.2/- each) Basic & Diluted	6.95	8.78	17.46
Research and Development Expenses	121.19	167.65	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.09.2023	30.09.2022	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,476.84	1,354.42	5,749.09
Profit Before Tax	133.84	167.80	345.63
Profit After Tax	135.84	145.44	346.73
Research and Development Expenses	126.70	167.65	699.58

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.bseindia.com and www.nseindia.com

For Alembic Pharmaceuticals Limited

30-

Place: Vadodra
 Date: 1st November, 2023

Chinyo Anir
 Chairman and CEO